Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

| OMB Number: 3235-028 | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|
| Estimated average burden | | | | | | | |
| hours per response: | 0.5 | | | | | | |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* LAUER REGAN J | | | | | 2. Issuer Name and Ticker or Trading Symbol ImmunityBio, Inc. [IBRX] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | |
|---|---------------------------------|--|--|---------------------|--|--|------------|--|--------|-----------------|--------|--------------------------------------|--|---|---|---------------------------------------|--|--|--|
| (Last) | | | (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 01/31/2024 | | | | | | | - x | below) | ficer (give title | | 10% Owner Other (specify below) | | | |
| C/O IMMUNITYBIO, INC. | | | | | | 01/31/2024 | | | | | | | | Chief Accounting Officer | | | | | |
| 3530 JOHN HOPKINS COURT | | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) | | | | | | | | | | | | X | Form fi | led by One | Reporting Perso | n | | | |
| SAN DIEGO CA 92121 | | | | | | | | | | | | | Form fi Person | | e than One Repo | rting | | | |
| (City) | (S | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | | | | | |
| | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | | | | |
| | | Tab | ole I - Noi | n-Deriv | ative Se | curities Acc | quired, | Disp | osed o | of, o | r Bene | eficially | y Owned | | | | | | |
| Date | | | | action Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year | 3. Transaction Code (Instr.) 8) | | | | | | | es ally following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership | | | | |
| | | | | | | | Code | v | Amount | (A) or (D) F | | Price | Reported Transaction(s) (Instr. 3 and 4) | | | (Instr. 4) | | | |
| Common Stock | | | | 01/31 | 1/2024 | | М | | 32,87 | 2 | Α | \$ <mark>0</mark> | 107 | ,804 | D | | | | |
| Common Stock 01/ | | | | 01/31 | 1/2024 | | F | | 13,47 | 0 | D | \$3.36 | 94 | ,334 | D | | | | |
| | | - | | | | urities Acqu s, warrants, | | | | | | | Owned | | | | | | |
| 1. Title of Derivative Security | 2. Conversion or Exercise | 3. Transaction Date (Month/Day/Year) | 3A. Deeme Execution if any | Date, 1 | 4. Fransaction Code (Instr. | of | Expiration | Date Exercisable and piration Date of Securities onth/Day/Year) Underlying Derivative Securities | | | ; | Derivative deriva Security Securi | | Ownership | 11. Nature of Indirect Beneficial | | | | |

| Security (Instr. 3) | or Exercise Price of Derivative Security | (Month/Day/Year) | if any (Month/Day/Year) | Code (Instr. 8) | | Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | (Month/Day/Year) | | Underlying Derivative Security (Instr. 3 and 4) | | Security (Instr. 5) | Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | |
|------------------------------|---|------------------|----------------------------|--------------------|---|---|--------|---------------------|--------------------|---|--|------------------------|--|--|---------------------------------------|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | |
| Restricted Stock Units | (1) | 01/31/2024 | | М | | | 32,872 | (2) | (2) | Common Stock | 32,872 | \$0 | 0 | D | | |

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

2. Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award vested on January 31, 2024.

Remarks:



02/02/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.